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c‑Jun and FOXO1 mediate the expression of oncogenic
PKC‑ι in human prostate cancer cells with an
interplay between NF‑κB, IL‑8 and ICAM‑1
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Received March 31, 2020; Accepted June 19, 2020
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Abstract. Aggressive and metastatic prostate cancers are
among the leading causes of fatality in men. Prior observations
by the authors regarding atypical protein kinase C isoforms
(aPKCs) in relation to prostate cancers demonstrated elevated
levels of PKC‑iota (PKC‑ι) in patient samples compared to
non‑malignant prostate tissues. This indicates that PKC‑ι is
a potential biomarker for initiating and maintaining prostate
carcinogenesis. In addition, PKC‑ι is an oncogene that encour‑
ages the activation of the nuclear factor (NF)‑κ B, assisting
carcinogenesis. The specific inhibition of PKC‑ι de‑regulated
the expression of both PKC‑ι and its phosphorylation; thus,
PKC‑ι functionally controls its own expression in prostate
carcinoma. The present study aimed to investigate the under‑
lying mechanisms of PRKCI gene transcriptional regulation in
prostate carcinoma cells. Forkhead box protein O1 (FOXO1)
and c‑Jun, along with several other transcription factors that
exhibited potential to bind on or near the promoter region
of the PRKCI were identified. Each transcription factor was
systematically silenced. The decrease in the expression levels
of FOXO1 and c‑Jun significantly affected PKC‑ι expression.
The decrease in FOXO1 expression by siRNA enhanced PKC‑ι
expression by 33% (P≤0.05) and 9% (P≤0.05) in the PC‑3 and
DU‑145 cells, respectively. The diminution of c‑Jun expression
by siRNA diminished PKC‑ ι expression by 42% (P≤0.05)
and 24% (P≤0.05) in the PC‑3 and DU‑145 cells, respectively.
According to the results of the present study, c‑Jun and FOXO1
are the two major transcription factors involved in PKC‑ ι
expression in prostate cells. PKC‑ι and its phosphorylation
improved due to FOXO1 diminution, and vice versa for c‑Jun
silencing, indicating that c‑Jun upregulates PRKCI expression,
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while FOXO1 negatively affects its expression. This was medi‑
ated through signal transducer and activator of transcription
(STAT)3/5 and NF‑κ B. An upregulation in the expression of
intercellular adhesion molecule 1 (ICAM‑1) and interleukin
(IL)‑8 was observed as a result of PKC‑ι specific inhibition.
PKC‑ι inhibition thus promotes ICAM‑1/FOXO1 signaling
and downregulates IL‑8/JNK/c‑Jun signaling, indicating that
PKC‑ι inhibition subdues its production mechanism. Overall,
an analysis of the results led us to suggest that PKC‑ι inhibition
downregulates its own oncogenic signaling, while the induc‑
tion of anti‑tumor signaling pathways strongly suggests that
PKC‑ι related molecular mechanisms provide a novel thera‑
peutic route for mitigating prostate cancer.
Introduction
The National Cancer Institute of the United States estimated
that approximately 175,000 new prostate cancer cases will
be identified in 2020, while there will be a projected 32,000
cancer‑related deaths among American males. Approximately
14% of men will acquire the disease throughout their life‑
times (1). To date, radiation therapy, chemotherapy and
hormone therapy are the most common treatments for PC.
Radiation therapy is not ideal as it destroys surrounding
healthy cells and tissues, leading to a number of side‑effects.
Hormone treatment implies clinical castration and the usage
of anti‑androgens, that can have adverse effects and can affect
the lifestyle of the recipient (2). Moreover, PC treatments
involve the use of chemotherapeutic agents, such as docetaxel.
Docetaxel only increases the survival time of the patient by
approximately 100 days, primarily due to the emergence of
resistance (3).
In previous studies by the authors, protein kinase C‑ ι
(PKC‑ι) was recognized as a major driving factor of prostate
and melanoma carcinogenesis, and was therefore proposed as
a potential and novel therapeutic target (4‑10). PKC is a part
of the protein kinase enzyme class that post‑translationally
modifies certain other proteins and participates in a variety
of cellular signaling cascades. A total of 15 PKC isoforms
are recognized in humans; these are further grouped as clas‑
sical, novel and atypical PKCs (aPKCs). aPKCs comprise two
structurally and functionally distinctive isoforms; PKC‑ζ and
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PKC‑ι (11‑13). Other than PC and melanoma, PKC‑ι has been
found to function as an oncogene in several other cancer types,
such as neuroblastoma, ovarian cancer and glioma, where the
upregulation of PKC‑ι expression has been shown to be associ‑
ated with a low survival rate (10,11,14). In previous studies by
the authors, it was also reported that higher levels of PKC‑ι
were observed in DU‑145 and PC‑3 cells compared to undetect‑
able levels in normal tissues and the normal prostate epithelial
cell line, RWPE‑1 (7,10). In addition, it was demonstrated that
PKC‑ι phosphorylates to activate Iκ B kinase (IKKα/β). This
p‑IKKα/β activation triggers the dissociation of nuclear factor
of κ light polypeptide gene enhancer in B‑cells inhibitor (Iκ B)
from the nuclear factor NF‑κ B complex, which leads to the
ubiquitination of Iκ B. Iκ B releasing from NF‑κ B activates the
translocation of NF‑κ B to the nucleus. Previous studies by the
authors suggested that PKC‑ι specific leads to the suppression
of NF‑κ B nuclei translocation, thereby causing a downregula‑
tion of NF‑κ B activity (9,10). These findings indicated that the
inhibition of PKC‑ι not only impaired pathways regulated by
PKC‑ι, but also downgraded its protein expression (7‑10). There
are data to suggest that PKC‑ι maintains a self‑propagative
mechanism, as observed in certain other cancer‑related cycles,
such as the transformation of the growth factor (TGF)‑β and
CD147 (15). Since transcription factors play a pivotal role in
gene expression, the aim of the present study was to determine
which transcription factors were key PKC‑ ι regulators, as
well as which pathways were integral components for these
transcription factors.
In the present study, the outcomes of the knockdown
of the expression of c‑Jun, FOXO1, PKC‑ι and NF‑κ B are
demonstrated, giving emphasis to pathways associated with
PKC‑ι. The findings suggested that c‑Jun is a crucial transcrip‑
tional activator, while FOXO1 functions as a transcriptional
suppressor of PRKCI expression. The roles performed by these
transcription factors were determined in an inflammatory
process that promotes PKC‑ι and is dependent on PKC‑ι for the
continuation of the process. Moreover, the pathway through
which cytokines stimulate PKC‑ι expression to release acti‑
vated NF‑κ B is demonstrated, which leads to the production
of additional cytokines; this process is used in certain types
of cancer as part of a loop through which to grow and propa‑
gate. In addition, IL‑8 promotes c‑Jun and NF‑κ B signaling
to enhance PKC‑ ι production. On the other hand, PKC‑ ι
inhibition induces the production of ICAM‑1, which promotes
FOXO1 to reduce PKC‑ι production. In general, these findings
indicate that with a dynamic and closely controlled expression
profile, PKC‑ι plays a central role in the development of pros‑
tate cancer. The specific inhibition of PKC‑ι may interact with
its own regulatory process, contributing to a distortion of its
oncogenic function in prostate cancer.

against PKC- ι (610175, BD Biosciences); NF- κ B p65
(sc-372-G, Santa Cruz Biotechnology, Inc.); p-PKC-ι (T555;
ab5813, Abcam); FOXO1 (2880S), p-FOXO1 (T24; 9464S),
c-Jun (9165S), p-c-Jun (S73; 3270S), mammalian target of
rapamycin (mTOR; 2972S), p-AKT (S473; 4059S), signal
transducer and activator of transcription (STAT)3 (9139S)
and STAT5 (25656S) (all from Cell Signaling Technology,
Inc.); and β -actin (A3854, Sigma-Aldrich; Merck KGaA);
enhanced chemiluminescence solution (34080, Pierce;
Thermo Fisher Scientific, Inc.); human small interfering RNA
(siRNA) for PKC-ι (SR303741), c-Jun (SR302499), FOXO1
(SR301618), early growth response 1 (EGR1; SR301358),
paired box gene 3 (PAX3; SR303360), interferon regulatory
factor 9 (IRF9; SR307030), NF-κ B p65 (SR321602) (all from
Origene Technologies, Inc.); DPBS without magnesium and
calcium ions (Dulbecco's phosphate-buffered saline, D8537),
Trypsin-ethylenediaminetetraacetic acid (EDTA; T4049,
Sigma-Aldrich; Merck KGaA); recombinant protein tumor
necrosis factor (TNF)- α (human, 10602HNAE25, Thermo
Fisher Scientific, Inc.).

Materials and methods

Knockdown of c‑Jun, FOXO1, PKC‑ι and NF‑κ B gene expres‑
sion by siRNA. The PC‑3 and DU‑145 (1x105) cells were seeded
in T25 flasks and at 24 h post‑seeding, siRNA (30 nM) trans‑
fections were conducted against scrambled siRNA for 2 days
using ‘siTran’ siRNA transfection reagent (TT300002) from
Origene Technologies, Inc. according to the manufacturer's
recommended ratios. The cell pellets were collected at the end
of the 48‑h incubation period and cell lysates were prepared
using cell lysis buffer (C7027, Thermo Fisher Scientific, Inc.).

Materials and reagents. [4-(5-Amino-4-carbamoylimidazol1-yl)-2,3-dihydroxycyclopentyl] methyl dihydrogen phosphate
(ICA-1T) was purchased by Therachem and the NF-κ B-specific
inhibitor, 4-methyl-N1-(3-phenylpropyl)-1,2-benzenediamine
(JSH-23, J4455), was purchased from Sigma-Aldrich; Merck
KGaA. Sterile distilled water was used as the solvent for the
inhibitors. The following materials were acquired: Antibodies

Cells and cell culture. DU‑145 (ATCC ® HTB81™) and
PC‑3 (ATCC® CRL‑1435™) cells were obtained from the
American Type Tissue Culture Collection (ATCC). All
cell lines were authenticated by ATCC using karyotyping,
morphology and PCR‑based approaches. Early passages of
cells were cryo‑preserved in liquid nitrogen and cells of early
passages were resuscitated from liquid nitrogen for experi‑
ments. A temperature of 37˚C and 5% CO2 were maintained
as the cell culture conditions. EMEM (ATCC 30‑2003) and
RPMI‑1640 media (ATCC 30‑2001) were used with fetal
bovine serum (FBS, 10% v/v) and penicillin (5 µg/ml) for the
DU‑145 and PC‑3 cells, respectively.
Identification of c‑Jun and FOXO1 as probable transcrip‑
tion factors to bind to the PRKCI promoter region. The
gene sequence of PRKCI which is located on chromosome 3
between bp170222365‑170305981 (3q26.2) was acquired from
ensemble.org (ENSG00000163558) (16,17). The promoter
sequence was identified by comparing the forward strand
sequence with the Eukaryotic Promoter Database (EPD,
https://epd.vital‑it.ch/index.php). The sequence between
bp170220768‑170225128 was selected and which contained
the promoter, promoter flank, enhancer and a motif feature.
Transcription factors that exhibited a probability to bind with
an accuracy >90% were selected using PROMO; a virtual labo‑
ratory for reviewing transcription factor binding sites in DNA
selected sequences (http://alggen.lsi.upc.es/). The PROMO
results were also compared with the Genomatix Matinspector
results to confirm the accuracy.

WORLD ACADEMY OF SCIENCES JOURNAL 2: 16, 2020

3

Western blot and densitometric analyses were executed as
previously described by Ratnayake et al (9,18).

quantify gene expression by the 2‑ΔΔCq method (Thermo Fisher
Scientific, Inc.).

Prostate cancer cellular cytokine expression analysis. The
cytokine array kit (ARY005B, R&D Systems) contained with
an enzyme‑linked immunosorbent assay (ELISA) was used
for the experiment. Approximately 1x105 cells were cultured
in T25 flasks (PC‑3 and DU‑145) and at 24 h post‑plating,
the cells were treated with a ICA‑1T (2.5 µM) for 2 consecu‑
tive days at 24‑h intervals. The cells were then collected and
cell lysates were prepared and administered according to the
manufacturer's instructions. The experiment was repeated and
TNF‑α (250 ng/ml) was added to the flasks 30 min prior to
the harvesting point. Total protein (150 µg) was used from
each sample and introduced to the immunoblots provided
and chemiluminescence images were acquired using ‘ECL
Western Blotting Substrate’ (Thermo Fischer Scientific,
PI32106). These images were then analyzed as instructed in
the cytokine array kit manual (ARY005B).

Statistical analysis. All data are presented as the means ± SD.
Statistical analysis was carried out using one or two‑way
ANOVA followed by Tukey's HSD test as multiple comparisons
tests using the statistical research online tool ‘VassarStats’.
P‑values ≤0.05 or ≤0.01 were considered to indicate statisti‑
cally significant or highly statistically significant differences,
respectively.

Immunopaired antibody detection assay. Approximately 1x105
cells (PC‑3 and DU‑145) were cultured in T25 flasks and ICA‑1T
(2.5 µM) treatments were conducted as descirbed above. Cells
were then collected and cell lysates was prepared to contain
the final total protein concentration >2 µg/ml. Samples were
sent to ActivSignal, LLC for analysis. The ActivSignal IPAD
assay is a multiplex ELISA‑based proprietary tool for evalu‑
ating multiple signaling cascades considering both upstream
and downstream targets. In total, >20 signaling pathways were
examined at once in a single well by assessing the expression
or protein phosphorylation of 70 human proteins targets.
Reverse transcription‑quantitative PCR (RT‑qPCR). RT‑qPCR
was performed on RNA isolated from PC‑3 and DU‑145 cell
lysates collected following ICA‑1T (with or without TNF‑α)
or siRNA treatments (as described in above) against their
respective controls. The detailed procedure was previously
described by Ratnayake et al (18). Total RNA was isolated
from the cell pellets using RNA lysis buffer (RNeasy mini
kit, 74104) from Qiagen, Inc. RNA was reverse transcribed
into cDNA with You‑Prime First Strand Beads (27‑9264‑01)
form GE Healthcare. qPCR was performed on cDNA using
the QuantStudio3 Real‑Time PCR system (Thermo Fisher
Scientific, Inc.). The following primers were used: PKC‑ ι
forward, TTGCAATGAGGTTCGAGACA and reverse, CTG
AGATGATACTGTACACGGG; c‑Jun forward, GTGCCG
AAA A AGGAAG CTG G and reverse, CTGCGT TAGCAT
GAGTTGGC; FOXO1 forward, ATGGCTTGGTGTCTTTCT
TTTCT and reverse, TGTGGCTGACAAGACTTAACTCAA;
IL‑8 forward, CAGAGACAGCAGAGCACAC and reverse,
ATCAGGA AGG CTG CCA AGAG; ICAM‑1 forward, GGG
AACAACCGGAAGGTGTA and reverse, CAGTTCCACCCG
TTCTGGAG; and β‑actin forward, AGAGCTACGAGCTGC
CTGAC and reverse, AGCACTGTGTTGGCGTACAG which
was used as an internal control. PCR reactions conditions
were used as explained by Livak and Schmittgen (19). PCR
reactions used SYBR‑Green PCR Mix (Applied Biosystems).
cDNA was denatured at 95˚C for 10 min, followed by 40 cycles
of denaturing at 95˚C for 20 sec and an annealing stage of
65˚C for 40 sec. QuantStudio Software 2.0 was used to

Results
The unique PRKCI sequence, carefully selected to contain
the promoter, promoter flank, enhancer and a motif element,
was 4,360 bp in length (chr3; bp170220768‑170225128). The
promoter allowed TFs to bind and start transcription, while the
enhancer ensured a regulating area on the flank that promoted
transcription factor binding. By having only transcription
factors, which bind within a dissimilarity range of approxi‑
mately 10%, potential hits were narrowed down to achieve a
high specificity. After analyzing the results, approximately
70 transcription factor hits to the target were obtained. c‑Jun,
ISGF3, PAX3, EGR1 and FOXO1 were identified as the top 5
transcription factors with the greatest likelihood of binding to
the PRKCI gene sequence.
c‑Jun and FOXO1 are the two key TFs of PKC‑ ι expression
in PC‑3 and DU‑145 cells. As presented in Fig. 1, the results
of western blot analysis revealed that each siRNA transfection
targeting FOXO1 and c‑Jun markedly diminished the expres‑
sion levels of those targets. siRNA against FOXO1 significantly
knocked down FOXO1 by 64% (P≤0.05) and 27% (P≤0.05),
while p‑FOXO1 (T24) by 19% (P≤0.05) and 79% (P≤0.05) in
the PC‑3 and DU‑145 cells, respectively. siRNA against c‑Jun
knocked down c‑Jun by 48% (P≤0.05) and 73% (P≤0.05), while
p‑c‑Jun (S73) by 26% (P≤0.05) and 43% (P≤0.05) in the PC‑3
and DU‑145 cells, respectively. These findings indicated that
transfection with siRNA knocked down the respective target
expression. Only the knockdown of c‑Jun and FOXO1 in both
cell lines was shown to have an affect on PKC‑ι levels. The
diminution of FOXO1 by siRNA increased total PKC‑ι expres‑
sion by 33% (P≤0.05) and 9% (P≤0.05) in the PC‑3 and DU‑145
cells, respectively. The diminution of c‑Jun by siRNA dimin‑
ished PKC‑ι expression by 42% (P≤0.05) and 24% (P≤0.05) in
the PC‑3 and DU‑145 cells, respectively. Similarly, lower levels
of FOXO1 due to transfection with siRNA augmented p‑PKC‑ι
(T555) expression by 18% (P≤0.05) and 22% (P≤0.05) in the
PC‑3 and DU‑145 cells, respectively. Of note, c‑Jun diminu‑
tion decreased PKC‑ι (T555) expression by 36% (P≤0.05) and
13% (P≤0.05) in the PC‑3 and DU‑145 cells, respectively. The
knockdown of the expression of ISGF3, EGR1 and PAX3 did
not exert notable effect on PKC‑ι expression or on its phos‑
phorylated protein levels; thus, these data were not included
in this manuscript. Hence, FOXO1 and c‑Jun were selected for
use in the following experiments.
In addition to the total and p‑PKC‑ι levels, the levels of
mTOR, STAT3, STAT5, NF‑κ B p65 and p‑AKT (S473) were
determined following transfection with c‑Jun and FOXO1
siRNA. Transfection with FOXO1 siRNA increased the
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Figure 1. Effect of RNA interference (siRNA) of the transcription factors, c‑Jun and FOXO1, in two prostate cancer cell lines (PC‑3 and DU‑145). (A) Expression
of the protein levels of phosphor‑PKC‑ι (T555), total PKC‑ι, c‑Jun, phosphor‑c‑Jun (S73), FOXO1, phosphor‑FOXO1 (T24), mTOR, STAT3, STAT5, NF‑κ B
p65 and phosphor‑AKT (S473) following the siRNA knockdown of the expression FOXO1 and c‑Jun for PC‑3 and DU‑145 cell lines. Total protein (80 µg) was
loaded into each well and β‑actin was used as the internal control in each western blot. (B) Representative densitometry values for the western blots shown
in (A) Experiments (n=3) were performed in each trial and representative bands are shown. Densitometry values are reported as the means ± SD. Statistical
significance is indicated by an asterisk (*P≤0.05).

expression of STAT3 by 29% (P≤0.05) and 27% (P≤0.05) in
the PC‑3 and DU‑145 cells, respectively. On the other hand,
transfection with c‑Jun siRNA reduced STAT3 expression by
16% (P≤0.05) and 20% (P≤0.05) in PC‑3 and DU‑145 cells,
respectively. Of note, transfection with FOXO1 and c‑Jun
siRNA did not exert a significant effect on STAT5 expres‑
sion. The knockdown of c‑Jun by siRNA deceased mTOR
expression by 37% (P≤0.05) and 25% (P≤0.05) in the PC‑3
and DU‑145 cells, respectively. FOXO1 diminution did not
alter the protein levels of mTOR. Transfection with FOXO1
siRNA increased the expression of p‑AKT (S473) by 21%
(P≤0.05) and 28% (P≤0.05) in the PC‑3 and DU‑145 cells,
respectively. Transfection with c‑Jun siRNA did not exert a
significant effect on the levels of p‑AKT (S473). Transfection
with FOXO1 siRNA increased the expression of NF‑κ B p65
by 15% (P≤0.05) and 18% (P≤0.05) in the PC‑3 and DU‑145
cells, respectively. On the other hand, the knockdown of c‑Jun
significantly deceased NF‑κ B p65 expression by 18% (P≤0.05)
and 12% (P≤0.05) in the PC‑3 and DU‑145 cells, respectively
(Fig. 1).

were not affected as a result of NF‑κ B depletion. Notably, the
p‑c‑Jun (S73) level was significantly decreased upon NF‑κ B
depletion. The total c‑Jun levels were not affected as a result
of NF‑κ B depletion. Similar outcomes were acquired with
JSH‑23 (100 nM) treatments. JSH‑23 is an established NF‑κ B
specific inhibition available on the market.
In addition, Fig. 3 demonstrates the effects of PKC‑ ι
knockdown or specific inhibition using ICA‑1T on total PKC‑ι,
p‑PKC‑ι (T555), FOXO1, p‑FOXO1, p‑AKT (S473), STAT3,
c‑Jun and p‑c‑Jun (S73) expression. Transfection siRNA
against PKC‑ι and ICA‑1T treatment yielded similar results.
The total PKC‑ι and p‑PKC‑ι levels decreased significantly
(P≤0.05) with PKC‑ι knockdown or inhibition. Of note, upon
the depletion of PKC‑ ι, the total FOXO1 levels increased
(P≤0.05), while the levels of p‑FOXO1 decreased, indicating
an upregulation of FOXO1 activity. Similarly, both the p‑AKT
(S473) and STAT3 levels significantly (P≤0.05) decreased
owing to the decrease in PKC‑ι expression. On the other hand,
the levels of c‑Jun or p‑c‑Jun were not substantially altered
following the depletion of PKC‑ι.

c‑Jun and FOXO1 regulate atypical PKC‑ ι expression
through NF‑ κ B and STAT3 signaling in prostate cancer
cells. As presented in Fig. 2, the findings of western blot
analysis revealed that the knockdown of NF‑κ B expression
by siRNA substantially increased the overall PKC‑ι levels
by 24 % (P≤0.05) and 17% (P≤0.05) in the PC‑3 and DU‑145
cells, respectively. The expression of p‑PKC‑ι (T555) was not
significantly altered. Of note, the FOXO1 and p‑FOXO1 levels

ELISA suggests the involvement of multiple pathways;
JNK/c‑Jun, NF‑κ B/AKT/FOXO1 and STAT3 for the regula‑
tion PKC‑ ι of expression. The specific inhibitor, ICA‑1T,
was to inhibit PKC‑ι, permitting us to gain a clearer view of
the mechanisms through which multiple cellular signaling
pathways may affect PC‑3 and DU‑145 cells in vitro owing
to PKC‑ι regulation. The IPAD assay is an ELISA series,
which enables several proteins to be identified simultaneously.
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Figure 2. Effect of siRNA of the transcription factor, NF‑κ B, and the NF‑κ B inhibitor, JSH‑23, on the expression of PKC‑ι and targeted transcription factors
in PC‑3 and DU‑145 cells. (A) Protein levels of phosphor‑PKC‑ι (T555), total PKC‑ι, NF‑κ B p65, c‑Jun, phosphor‑c‑Jun (S73), FOXO1 and phosphor‑FOXO1
(T24) following the siRNA knockdown of the expression of NF‑κ B and JSH‑23 treatments for PC‑3 and DU‑145 cell lines. Total protein (80 µg) was loaded
into each well and β ‑actin was used as the internal control in each western blot. (B) Representative densitometry values for the western blots shown in
(A) Experiments (n=3) were performed in each trial and representative bands are shown. Densitometry values are reported as the means ± SD. Statistical
significance is indicated by an asterisk (*P≤0.05).

Fig. 4 demonstrates the changes in the expression of CD44,
E‑cadherin, caspase‑3, H2AX, Iκ B and Myc, and the degree
pf phosphorylation of p‑4E‑BP1 (T37/46), p‑AKT (S473),
p‑β‑catenin (S33/37), p‑HER3 (Y1289), pIKKαβ (S176/180),
p‑JNK (T183), p‑mTOR (S2448), p‑NF‑κ B p65 (S536), p‑Met1,
p‑STAT3 (Y705), p‑STAT5 (Y694) and p‑ZAP70 (Y493), as
a result of ICA‑1T inhibition against the respective control
samples for both PC‑3 and DU‑145 cell lines. The present study
observed that the levels of p‑JNK (T183) p‑mTOR (S2448)
and p‑ZAP70 (Y493) significantly increased in DU‑145 cells

following PKC‑ι inhibition, while those of p‑AKT (S473) and
p‑β‑catenin (S33/37) significantly decreased in DU‑145 and
PC‑3 cells, respectively.
IL‑8/c‑Jun and ICAM‑1/FOXO1 affect PKC‑ ι regulation
positively and negatively. As revealed in Fig. 5, immunoblot
analysis of cytokines in the PC‑3 and DU‑145 cell lines demon‑
strated a significant increase in the levels of IL‑8 and ICAM‑1
in the cells treated with ICA‑1T. IL‑1α, IL‑1β, IL‑18, CXCL‑1,
CXCL‑12, GM‑SCF, MIF and Serpin E1 were also found at
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Figure 3. Effect of siRNA of PKC‑ι and the PKC‑ι specific inhibitor, ICA‑1T, on the expression of PKC‑ι and targeted proteins in PC‑3 and DU‑145 cells.
(A) Protein levels of phosphor‑PKC‑ι (T555), total PKC‑ι, c‑Jun, phosphor‑c‑Jun (S73), FOXO1, phosphor‑FOXO1 (T24), STAT3 and phosphor‑AKT (S473)
following the siRNA knockdown of the expression of PKC‑ι and ICA‑1T treatments for PC‑3 and DU‑145 cell lines. Total protein (80 µg) was loaded into each
well and β‑actin was used as the internal control in each western blot. (B) Representative densitometry values for the western blots in (A) Experiments (n=3)
were performed in each trial and representative bands are shown. Densitometry values are reported as the means ± SD. Statistical significance is indicated by
an asterisk (*P≤0.05).

detectable levels, although the levels of these cytokines were
not altered substantially owing to PKC‑ ι inhibition, apart from
CXCL‑1, which exhibited a significant (P≤0.05) change in
PC‑3 cells. These results of PKC‑ι inhibition by ICA‑1T were
compared to the samples treated with TNF‑α prior to extrac‑
tion. TNF‑α, a cytokine known to upregulate NF‑κ B signaling,
did lead to a significant change in the expression profiles with

ICA‑1T treatments. As shown in Fig. 6A, RT‑qPCR analyses
were also conducted for these samples for which the western
blot data was presented in Fig. 5. As shown in Fig. 6A, the
PKC‑ι mRNA levels significantly decreased by 32% (P≤0.05)
and 23% (P≤0.05) in the PC‑3 and DU‑145 cells treated with
ICA‑1T, respectively. Along with PKC‑ι depletion, ICAM‑1
expression increased significantly by 45% (P≤0.05) and
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Figure 4. Immunopaired antibody detection assay (IPAD) for PC‑3 and DU‑145 cells. (A and B) expression of IPAD assay targets for PC‑3 and DU‑145 cell
lines, respectively. Approximately 1x105 cells were cultured in T75 flasks and 24 h post‑plating, fresh medium was supplied and the cells were treated with
either volume of sterile water (control) or the IC50 concentration of ICA‑1T (2.5 µM). Additional concentrations were supplied every 24 h during a 3‑day incu‑
bation period. The cells were then lysed and prepared lysates with the final total protein concentration to be >2 µg/ml and then sent to ActivSignal, LLC facility
to conduct the IPAD assay. IPAD platform is a proprietary multiplexed ELISA technology for analyzing the activity of multiple signaling pathways in one
reaction. Activities of multiple signaling pathways were monitored simultaneously in a single well through assessing the expression or protein phosphorylation
of 25 target human proteins, such as caspase‑3, CD44, CHOP, E‑cadherin, Iκ Bα, Myc, NOTCH, p‑4E‑BP1, p‑AKT (S473), p‑β‑catenin, p‑HER3, p‑IRS‑1,
p‑JNK, p‑MEK1, p‑mTOR, p‑NF‑κ B, p‑NUMB, p‑SMAD1, p‑SMAD2, p‑STAT3, p‑STAT5, p‑YAP1, p‑ZAP70, p21 and PARP. α‑tubulin and β‑tubulin were
used as internal controls in each trial. Experiments (n=3) were performed in each cell lines and the means ± SD are plotted. Statistical significance is indicated
by an asterisk (*P≤0.05).

93% (P≤0.05) in the PC‑3 and DU‑145 cells, respectively.
Additionally, the IL‑8 levels also increased significantly by
123% (P≤0.05) and 50% (P≤0.05) in the PC‑3 and DU‑145
cells, respectively.
Fig. 6B demonstrates the mRNA levels of PKC‑ι, c‑Jun,
FOXO1 and NF‑κ B in the cells subjected to the knockdown
of FOXO1, c‑Jun and NF‑κ B p65 by siRNA for both cell
lines with respect to the controls. Fig. 6B demonstrates the
results of mRNA expression analysis following transfection
of the cells with siRNA against FOXO1, c‑Jun and NF‑κ B
in which the western blot analysis data are presented in
Figs. 1‑3. The mRNA analysis for these siRNA transfections
confirmed the western blot analysis observations presented
in Figs. 1‑3. The diminution of FOXO1 led to an increase in
PKC‑ι expression by 134 and 68% (P≤0.05) in the PC‑3 and
DU‑145 cells, respectively. Additionally, the diminution of

c‑Jun expression decreased PKC‑ι expression by 38 and 18%
(P≤0.05) in the PC‑3 and DU‑145 cells, respectively. These
outcomes confirmed that FOXO1 functions as a transcriptional
deactivator for expressing the PRKCI gene, while c‑Jun func‑
tions as a transcriptional activator.
Fig. 7 presents a graphical overview of PKC‑ι expression
modulation in prostate cancer cells based on the present study
current and on previous evidence (7,10,18). This illustration
reveals the connections between multiple pathways of JNK,
NF‑κ B, AKT/FOXO1 and STAT3 in relation to PKC‑ι regula‑
tion. It indicates that PKC‑ι plays a vital role in controlling its
expression via the c‑Jun and FOXO1 transcriptional activation/
deactivation. Owing to c‑Jun transcriptional function, PKC‑ι is
overexpressed with the aid of pro‑survival, oncogenic STAT3,
NF‑κ B/PI3K/AKT and signaling cascades. PKC‑ι inhibition
using ICA‑1T pledges an interruption to PKC‑ ι expression
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Figure 5. Cytokine expression analysis of prostate cancer cells upon PKC‑ι inhibition using ICA‑1T in the presence and absence of TNF‑α. (A and B) Western
blot array of the PKC‑ι inhibition for PC‑3 and DU‑145 cells against the controls. (C and D) The quantified results of the western blots shown in (A and B) for
the PC‑3 and DU‑145 cells, respectively. CXCL‑1, CXCL‑12, GM‑SCF, ICAM‑1, IL‑1α, IL‑1β, IL‑6, IL‑8, IL‑18 and MIF were found in detectable levels
in western blot analysis for PC‑3 and DU‑145 cell lysates. Experiments (n=3) were performed in each cell lines and the means ± SD are plotted. Statistical
significance is indicated by an asterisk (*P≤0.05).

Figure 6. (A) RT‑qPCR analysis of cytokines (ICAM‑1, IL‑6, IL‑8 and CXCL‑1) and PKC‑ι for the PKC‑ι specific inhibition using ICA‑1T in the presence and
absence of TNF‑α for PC‑3 and DU‑145 cells respectively. (B) RT‑qPCR analysis of FOXO1, c‑Jun, PKC‑ι and NF‑κ B following the siRNA knockdown of
FOXO1, c‑Jun and NF‑κ B for PC‑3 and DU‑145 cells. All targeted mRNA levels were plotted against β‑actin as the internal control. Experiments (n=3) were
performed in each cell line and the means ± SD are plotted. Statistical significance is indicated by an asterisk (*P≤0.05).

cycles through the downregulation of the NF‑κ B pathway by
limiting IKKα/β due to the limitation of activated p‑PKC‑ι.
It caused a suppression of NF‑κ B transcriptional activity and
IL‑8. Due to the lack of NF‑κ B stimulation, IL‑8 accumulates
in the cytosol and does not perform its intended paracrine
further upregulation of PI3K/AKT signaling. AKT signaling
decreases due to the lack of cytokine activation, such as
IL‑8, which ultimately contributes to FOXO1 upregulation.
FOXO1 adversely governs the expression of PKC‑ι and also
decreases the function of JNKs to postpone its activation of
c‑Jun which upregulates the expression of PKC‑ι. Moreover,
FOXO1 downregulates STAT3 and NF‑κ B signaling. The
cycle persists and contributes to the further downregulation of
NF‑κ B and c‑Jun, and the upregulation of FOXO1, decreasing

PKC‑ι expression. The whole process began upon the inhibi‑
tion of PKC‑ι. As a result of this signaling alteration, the total
PKC‑ι level decreases in the tested prostate cancer cells. The
results of the present study closely reinforce the findings of
our previous study, wherein precise inhibition utilizing PKC‑ι
inhibitors decreased overall PKC quantities (10).
Discussion
In our previous study, the selective binding of ICA‑1T to an
allosteric site located in the C‑lobe of PKC‑ι kinase domain
was recognized. This binding led to the inhibition of PKC‑ι
activity (9). This consequentially leads to a reduction in
cellular differentiation, proliferation, migration and invasion,
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Figure 7. A schematic summary of the regulation of the expression of PKC‑ι in PC‑3 and DU‑145 cell lines. This model depicts how the crosstalk occurs
between the NF‑κ B, PI3K/AKT/FOXO1, JNK/c‑Jun and STAT3/5 signaling pathways during the PKC‑ ι regulation. It is shown that PKC‑ ι plays a very
important role in the regulation of its expression in a complex signaling network through the transcriptional activation/deactivation of c‑Jun and FOXO1. The
PKC‑ι‑specific inhibition by ICA‑1T, downregulates the NF‑κ B, STAT3 and IL‑8 activities. As a result, the activity of AKT decreases, which leads to the
upregulation of FOXO1, which turns out to be the most important transcription factor regulating PKC‑ι expression upon receiving stimulation from ICAM‑1.
FOXO1 downregulates the expression of PKC‑ι, suppressing JNK activity to attenuate the activation of c‑Jun. This reduces c‑Jun expression. This whole
process continues and leads to the further downregulation of NF‑κ B and c‑Jun, while upregulating FOXO1, which leads to the continuation of the depletion
of PKC‑ι expression in the cell lines. PKC‑ι inhibition leads to a decrease in its own production while enhancing multiple antitumor/pro‑apoptotic signaling.

whilst simultaneously driving the apoptosis of prostate cancer
cells via the diminution of the NF‑κ B pathway in vitro.
Subsequently, PKC‑ι was established as a key factor in the
induction of cell growth, differentiation and survival (8,9,11).
It was also recognized that PKC‑ι undergoes self‑regulation as
a consequence of its inhibition and a decrease in its expression
in the PC‑3 and DU‑145 cell lines. Thus, the aim of the present
study was the identification of the underlying processes of
PKC‑ι regulation in the aforementioned cell lines in vitro.
In order to investigate PKC‑ι regulation and expression, the
roles of transcription factors which interacted with the PRKC1
promoter region were investigated. The gene which codes of
PKC‑ι is the PRKCI gene, which is positioned on chromo‑
some 3 (3q26.2), which is an amplicon known to undergo
replication events (20). In order to deduce key TFs in PRKCI
regulation, a sequence encompassing the PRKCI promotor
with a motif feature was selected, as well as a promoter flank
and an enhancer. This was selected as it provides the ideal
platform in which the TFs can bind to regulate transcription.
Two systems, PROMO and Genomatix Matinspector, were

utilized to predict probable transcription factor bindings. This
led to the identification of 5 TFs two of which were FOXO1
and c‑Jun. Subsequently, these TFs were silenced in order
to analyze the downstream effect they would have on PKC‑ι
expression.
c‑Jun was the first transcription factor found to be associ‑
ated with numerous types of cancer, including metastatic breast
cancer and non‑small lung cancer (21). It functions through the
formation of an early response complex containing AP‑1 and
c‑Fos (22). The activation of c‑Jun occurs via phosphorylation
events by c‑Jun N‑terminal kinases (JNKs) on S63 and S73,
and is regulated via multiple extracellular stimuli, i.e., cyto‑
kines (23). Upon phosphorylation at S63 and S73, not only is
c‑Jun activated, but it also leads to an increase in the transcrip‑
tion of c‑Jun‑targeted genes. Extracellular signal‑regulated
kinase (ERK) is also upregulated by activated c‑Jun (24‑26).
c‑Jun is also known to promote the oncogenic transformation
of ‘ras’ and ‘fos’ in several cancer types (27,28). FOXO1 is
known to play a role in regulating various metabolic pathways,
such as gluconeogenesis, adipogenesis and insulin signaling.
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Similar to c‑Jun, phosphorylation plays a crucial role in FOXO1
function (29,30). FOXO1 is deactivated by AKT through
phosphorylation on T24, leading to the induction of nuclear
exclusion, which leads to ubiquitylation (31,32). Therefore,
it is important to note that the phosphorylation of FOXO1
indicates its inactivation and the downregulation of FOXO1
signaling. In relation to cancer, FOXO1 is a well‑established
tumor suppressor (33‑35). As such, there is a known associa‑
tion between FOXO dysregulation and cancer progression, as
it is also plays a role in both intrinsic and extrinsic pathways
of apoptosis (36,37). Experiments in vitro and in vivo have
confirmed that the overexpression of FOXO1 causes a reduc‑
tion in cell migration, proliferation and tumorigenesis in
cancer cells (38). Furthermore, ERK1/2, PKC‑ι and AKT can
downregulate FOXO1 (35). Thus, in the present study, it was
demonstrated that through the specific inhibition of PKC‑ι, the
expression of active PKC‑ι decreases, which renders it ineffec‑
tive in its role to deactivate FOXO1 through phosphorylation
events. This is a crucial indication of PKC‑ι involvement in the
regulation of its own expression, as PKC‑ι inhibition leads to
the continuous upregulation of FOXO1.
At the same time, previous data have demonstrated that
the inhibition of PKC‑ι causes the significant downregulation
of the PI3K/AKT pathway and in particular, downregulates
the activation of AKT (10). In the present study, as shown in
Figs. 3 and 6, NF‑κ B downregulation led to elevated levels of
active c‑Jun (phospho c‑Jun), which upregulated PKC‑ι expres‑
sion. These results validate our previous observation that
PKC‑ι inhibition, by which the phosphorylation of IKKα /β
is reduced, inhibits NF‑κ B activation and translocation to
the nucleus (10). Subsequently, NF‑κ B depletion induces an
increase in c‑Jun expression, which then attempts to increase
the production of PKC‑ι, which then needs to phosphorylate
IKKα/β to restore NF‑κ B signaling. The tight regulation of
PKC‑ι expression through c‑Jun may explain these results as it
enhances PRKCI transcription. There was also no significant
alteration in the levels of FOXO1 and phosphorylated FOXO1
resulting from NF‑κ B siRNA knockdown. This suggests that
the downregulation of NF‑κ B does not disrupt PKC‑ι expres‑
sion through FOXO1, but rather that c‑Jun provides cancer cells
with resistance to apoptosis through interplay with NF‑κ B
upon cytokine stimulation (21). In our previous study, it was
demonstrated that in melanoma, TNF‑α upregulates NF‑κ B,
phosphor‑AKT and PKC‑ι expression (9). However, the results
of the present study demonstrate that c‑Jun ‘switches on’
PKC‑ι expression and FOXO1 ‘switches off’.
Apart from identifying c‑Jun and FOXO1 out of 5 TFs
which could bind to the PKC‑ι gene promoter region, other key
molecular factors were also identified. Through the conduction
of ELISA using IPAD assay and a cytokine array, crosstalks
between multiple pathways were examined. The data indicated
links between PKC‑ ι expression with cytokines IL‑8 and
ICAM‑1, along with some other key cellular signaling points.
As shown in Fig. 4, the IPAD ELISA data revealed that
there was a significant increase in the expression levels
of p‑STAT3 (Y705), p‑JNK (T183) and p‑mTOR, whilst
displaying a significant decrease in p‑AKT (S473), p‑β‑catenin
and CD44 levels. Moreover, it has been demonstrated that
irregular STAT3/5 is associated with the progression of
various cancer types (39‑44). Cell survival in multiple

cancers has been shown to be induced by upregulated STAT
signaling, which is often stimulated by the cytokines, IL‑6 and
IL‑8 (39,40,45). STAT3 signaling enhances the production of
c‑Jun, thereby inducing c‑Jun‑targeted transcription (39,46).
The IPAD data of the present study strongly suggested that
STAT3 was upregulated due to PKC‑ι inhibition, suggesting
that the deprivation of PKC‑ι tries to accelerate the production
of c‑Jun through the upregulation of STAT3, JNK and mTOR.
Connections between the JNK pathway and FOXO1 have been
explored in few studies (35,47,48). Hornsveld et al summa‑
rizes the tumor‑suppressing features of FOXO1 resulting in a
decreased JNK activity (47). Whilst JNK activates c‑Jun, by
contrast, PKC‑ι inhibition renders it ineffective at increasing
c‑Jun or phospho‑c‑Jun levels, as can be seen in Fig. 3. Instead,
the FOXO1 levels were increased, while the phosphor‑FOXO1
levels along with the levels of phosphor‑AKT and STAT3 were
reduced in both cell lines. This demonstrates that the activa‑
tion of FOXO1 leads to a reduction in c‑Jun levels by blocking
the activity of phosphor‑JNK. Therefore, it was deduced that
FOXO1 plays a major role in c‑Jun regulation only upon
PKC‑ι inhibition. This process likely employs multiple mecha‑
nisms, such as JNK signaling inhibition, causing the further
retardation of PKC‑ι expression, which will eventually lead
to cell cycle arrest. This is further corroborated by FOXO1
being established as being able to induce cell cycle arrest. It
accomplishes this through the promotion of the transcription
of cell cycle kinase inhibitors or cyclin‑dependent kinase
inhibitor (CKI). p21 and p27 are two of the most well‑known
FOXO‑induced downstream CKIs (35,47). FOXO1 has also
been shown to be associated with the induction of anoikis
(apoptosis that occurs when cells detach from the extracellular
matrix) (47). Once again, this displays another downstream
effect of PKC‑ι involvement, as the inhibition of its expression
augments FOXO1 antitumor activity.
As shown in Fig. 7, it is summarized that the expression of
PRKCI is negatively affected by FOXO1, whilst being posi‑
tively affected by c‑Jun. The inhibition of PKC‑ι leads to the
following downstream effects. The downregulation of NF‑κ B
activity through the lack of phosphor‑IKKα/β, decreases the
levels of phosphor‑AKT (S473), thereby diminishing AKT
activity. Subsequently the low activity of AKT, along with
PKC‑ι, lead to the decreased phosphorylation of FOXO1, also
leading to elevated levels of active unphosphorylated FOXO1.
These elevated levels of activated FOXO1 lead to the further
suppression of PRKCI gene expression. This acts as a ‘switch
off’ effect on PRKCI expression. PKC‑ι downregulation also
leads to decreased STAT3, mTOR and JNK signaling. As a
consequence, this reduces c‑Jun activity, leading to the cancel‑
lation of the positive effects of c‑Jun towards PKC‑ι expression.
Furthermore, STAT3 and STAT5 upregulate NF‑κ B transcrip‑
tion in addition to c‑Jun (46,49). Due to this, it was deduced
that PKC‑ι inhibition causes the downregulation of NF‑κ B
and STAT3, leading to a decrease in both the transcription
and activation of c‑Jun. Therefore, these data suggest that
the PKC‑ι levels were decreased when c‑Jun expression was
silenced by siRNA (Figs. 1 and 6B).
In the present study, further in vitro experiments (Figs. 5
and 6A) demonstrated the deviations in cytokine expression
(IL‑8 and ICAM‑1) in the PC‑3 and DU‑145 cells upon PKC‑ι
knockdown. In both cell lines, the protein levels of IL‑8
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and ICAM‑1 (as well as their mRNA levels) were shown to
undergo a significant intensification following PKC‑ι knock‑
down by siRNA, as proven by western blot and RT‑qPCR
analyses. These data suggest that PKC‑ ι self‑regulation is
involved in autocrine signaling. Tumor cellular environments,
with prostate cancer in particular, are constantly exposed
to a variety of immune cells and inflammatory factors. The
effects of which function to either promote chronic inflamma‑
tion or engage in antitumor activity (50). Examples of these
inflammatory factors are cytokines; they play a crucial role
in controlling the tumor microenvironments (51). To achieve
their functions, cytokines utilize multiple signaling pathways.
They can either act to promote or downregulate tumor progres‑
sion and metastasis. Examples of tumor promoting cytokines
are; as CXCL‑1, CXCL‑12, IL‑18, CXCL‑10, IL‑6 and IL‑8.
CXCL1, also known as melanoma growth‑stimulatory activity/
growth‑regulated protein α, functions in processes of wound
healing, angiogenesis and inflammation after being secreted
by cancer cells. It has also been linked to tumor formation (52).
Metastatic regulation has also been linked to high levels of
CXCL10/CXCR3, with CXCL10 playing an important role in
the promotion of tumor growth and metastasis (52). Metastatic
regulation has also been linked to high levels of CXCL10/
CXCR3, with CXCL10 playing an important role in the
promotion of tumor growth and metastasis (52,53). CXCL12
(stromal‑derived factor‑1) utilizes the receptors CXCR4 and
CXCR7 and it has been linked to playing a role in the regula‑
tion of tumor metastasis. However, CXCL‑10, CXCL‑12 and
IL‑18 were not observed as being significantly altered as result
of PKC‑ι inhibition.
IL‑6 has been linked to the stimulation of the degrada‑
tion of Iκ B‑ α, which in turn results in the upregulation of
NF‑κ B translocation. As previously demonstrated, PKC‑ ι
stimulates NF‑κ B translocation through Iκ B‑α degradation (9).
Upon translocation to the nucleus, NF‑κ B induces cell survival
via the transcription of multiple survival factors and cyto‑
kines (39,45,53), with IL‑8 being one such cytokine. It plays
a key role in the regulation of polymorphonuclear neutrophil
mobilization. It is also associated with the extravasation in the
steps of cancer metastasis. IL‑8 has been shown through studies
to be regulated by NF‑κ B in prostate cancer cells. As such, an
increased IL‑8 expression has been connected to the promo‑
tion of a favorable microenvironment for metastasis (54,55).
Notably, the findings of the present study demonstrated that
upon transfection with PKC‑ ι siRNA, the IL‑8 expression
levels increased. This may be a result of a backup mechanism
in order to upregulate IL‑8. IL‑8 also plays an essential role in
upregulating c‑Jun through JNKs. As the inhibition of PKC‑ι
downregulates c‑Jun, the cells may be attempting to reinstate
these downregulated pathways by a higher IL‑8 production.
As shown in Fig. 7, the expression of IL‑8 is regulated through
both NF‑κ B and STATs. These results indicate that IL‑8 is
important in upregulating PKC‑ι expression, activating c‑Jun,
while deactivating FOXO1. Though it would appear that due to
the high activity of FOXO1, the effect of IL‑8 are canceled out.
Through utilizing an immune response, some cytokines
promote antitumor activity. One such cytokine is ICAM‑1,
which plays a role in the immune response, including antigen
recognition and lymphocyte activation (56,57). As such,
ICAM‑1 has beeb linked to the inhibition of tumor progression
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via the inhibition of the PI3K/AKT pathway. In its role in
inhibiting this pathway, ICAM‑1 exposes tumor cells to attack
and death through cytotoxic T‑lymphocytes (57). ICAM‑1
expression inhibition has also been shown in clinical research
to be associated with an increased risk of metastasis within
the first 5 years of ovarian cancer diagnosis (57). Of note,
the results of the present study demonstrated that upon the
silencing of PKC‑ι by siRNA, the ICAM‑1 levels increased.
This confirmed that upon the knockdown of oncogenic PKC‑ι,
antitumor/pro‑apoptotic signaling was upregulated through
an autocrine manner via ICAM‑1. Furthermore, these results
demonstrate that ICAM‑1 plays an important downregulatory
role in the regulation of PKC‑ι expression along with FOXO1,
opposite to c‑Jun and IL‑8.
To conclude, the results of the present study illustrate
that PKC‑ι plays an imperative role in its own expression via
an intricate signaling grid that involves the transcriptional
activation/deactivation of c‑Jun and FOXO1. The inhibition of
PKC‑ι activity, based on its specific inhibition, downregulates
the NF‑κ B pathway along with the transcriptional activity of
STAT3 and IL‑8. The results in a decrease in AKT activity
that leads to FOXO1 upregulation. FOXO1 was identified to
be the most important transcription factor when it comes to
regulating PKC‑ι, along with ICAM‑1 stimulation. FOXO1
negatively regulates PKC‑ ι expression, diminishing JNK
activity and further suppressing the activation of c‑Jun. The
consequence of this process is that it leads to the downregu‑
lation of NF‑κ B and c‑Jun, and further upregulates FOXO1.
This continues to deplete the PKC‑ι expression, subsequently
leading to a decrease in the total PKC‑ ι levels in prostate
cancer cells. The regulation of PKC‑ι is complex, and PKC‑ι
itself plays a key role in that process. As such, when inhib‑
ited, it leads to a decrease in PKC‑ι production, prompting
multiple antitumor/pro‑apoptotic signaling. PKC‑ι is therefore
a key factor to target when attempting to treat prostate cancer
in vitro. Finally, the results of the present study demonstrate
that PKC‑ι is not only a novel biomarker to target for personal
therapeutics for prostate cancer, but also that ICA‑1T shows
promise as one such therapy in relation to the proposed
mechanism.
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